Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Sanofi’s consumer health division ... and promote regeneration in chronic conditions such as fibrostenosing Crohn’s disease ...

Kymera Therapeutics is pivoting focus from oncology to immunology, with plans to only develop cancer programs beyond phase 1 studies via partnerships. | Kymera Therapeutics is pivoting its focus from ...

In addition, Sanofi’s decision to expand both the HS and AD studies ... KT-621 has the potential to address numerous TH2 diseases including atopic dermatitis, asthma and COPD, among others. In October ...

Opella Valuation: EUR16 billion EV, 14 times 2024 estimated EBITDA. Sanofi SA (NASDAQ:SNY) reported a strong sales performance with Q3 sales reaching EUR13.4 billion, marking a 16% increase in ...

Sanofi will keep a significant stake in the company ... Dupixent is now approved for COPD in more than 30 countries, including the US and China, where COPD is a huge unmet medical need due to ...

Sanofi attributed its double-digit growth to growth in vaccines, particularly its latest flu jab. Another major revenue contributor was Dupixent, the company's COPD treatment, whose sales surged ...